Sapience receives orphan designation for ST101 to treat advanced melanoma
This is the third orphan drug designation received by Sapience for ST101, a first-in-class peptide antagonist of C/EBPβ. The FDA granted orphan designations to ST101 for AML treatment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.